Our results agree with previous reports of enhanced glycolysis in MASLD due to increased mRNA levels of glycolytic enzymes (HK2 and PKM2) [68] and the augmented liver glucose phosphorylating activity of hexokinase [69]. Here, PKM is linked to metabolic dysfunction-associated steatotic liver disease.